Oxford Biomedica PLC Notice of Interim Results (2575X)
August 27 2020 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 2575X
Oxford Biomedica PLC
27 August 2020
Notice of Interim Results
Oxford, UK - 27 August, 2020: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, will be announcing its interim results for the six
months ended 30 June 2020 on Thursday 17 September 2020.
A virtual briefing and Q&A session for analysts will be held
at 13.00 BST / 08.00 EST on the day of results, and the
presentation and webcast details will be made available on the
Group's website at www.oxb.com . A replay webcast will be made
available shortly afterwards.
-Ends-
Enquiries:
Oxford Biomedica plc T: +44 (0)1865 783 000
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 954 161 / E: ir@oxb.com
Catherine Isted, Head of Corporate
Development & IR
T: +44 (0)20 3709 5700 /
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen,
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy
Consortium and Imperial Innovations, through which it has long-term
economic interests in other potential gene and cell therapy
products. Additionally the group has signed a Clinical and
Commercial Supply Agreement with AstraZeneca for manufacture of the
adeno based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica
is based across several locations in Oxfordshire, UK and employs
more than 550 people. Further information is available at
www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORQQLFLBVLEBBQ
(END) Dow Jones Newswires
August 27, 2020 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024